Paige
Paige is an AI-powered digital pathology company developing artificial intelligence applications for cancer detection and diagnosis. The company leverages proprietary deep learning models and one of the world's largest clinically annotated datasets of digitized pathology slides (7+ million slides) from Memorial Sloan Kettering Cancer Center to develop FDA-cleared and CE-marked diagnostic tools for pathologists and oncologists.
Acquired
Paige has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
100–200
Total Funding
$301.25M
6 rounds
Latest Valuation
$0.08B
Aug 22, 2025
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $301.25M across 6 rounds
Last updated 06-25-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Aug 22, 2025 | Acquisition by Tempus Press release | $81.25M | $0.08B | Tempus AI |
| 2023 | Series C Extension | $25M | — | Not disclosed |
| Jan 14, 2021 | Series C Press release | $100M | — | Casdin Capital, Johnson & Johnson Innovation |
Leadership
Thomas Fuchs
Co-Founder, Chief Scientist
David Klimstra
Founder, Chief Medical Officer
Andy Moye
Chief Executive Officer
Jill Stefanelli
President, Chief Business Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
PathAI
AI-powered research tools and services for pathology, delivering diagnosis and treatment of cancer through machine learning approaches
Ibex
AI-based cancer diagnostics company providing diagnostic solutions for pathology that assist in detecting cancer and tissue features
Owkin
Develops AI-based decision-support tools for pathology, including microsatellite instability detection in colorectal cancer
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.